Skip to main content
SpringerLink
Log in

Malignant melanoma: prevalence increasing and still no magic bullet

  • New Drugs and Disease Management
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Noble S, Goa K. Aldesleukin (recombinant interleukin-2). A review of its pharmacological properties, clinical efficacy and tolerability in patients with metastatic melanoma. BioDrugs 1997 May; 7(5): 394–422

    CAS  Google Scholar 

  2. American Cancer Society. Skin cancer. In: Cancer facts & figures — 1997. American Cancer Society; 1997 [online]. Available from URL: http://www.cancer.org/97skin.html [Accessed 1997 Feb 3]

  3. Melanoma: a lifestyle disease. Aust J Pharm 1997 Aug; 78: 846–7

    Google Scholar 

  4. Anderson CM, Buzaid AC, Legha SS. Systemic treatments for advanced cutaneous melanoma. Oncology 1995 Nov; 9(11): 1149–58

    PubMed  CAS  Google Scholar 

  5. Barth A, Wanek LA, Morton DL. Prognostic factors in 1,521 melanoma patients with distant metastases. J Am Coll Surg 1995; 181(3): 193–201

    PubMed  CAS  Google Scholar 

  6. Skin cancer: diagnosis, current treatment and future therapy. Drug Mark Dev 1997 Aug 1; 8(8): 170–6

    Google Scholar 

  7. Elwood W. Where next in immunotherapy for melanoma? Inpharma 1997 Jun 28; 1093: 9–10

    Google Scholar 

  8. Intron A approved in EC for melanoma. Scrip 1997 Aug 8; 2256: 16

    Google Scholar 

  9. British National Formulary No. 33. London: The Pharmaceutical Press, 1997 Mar: 369

  10. Elwood W. Sunrise on therapeutic melanoma vaccines? Inpharma 1997 Jul 5; 1094: 3–4

    Google Scholar 

  11. von Eschen KB, et al. Phase III trial of melacine® melanoma theraccine versus combination chemotherapy in the treatment of stage IV melanoma. Melanoma Research 1997 Jun; 7 (Suppl. 1): S51

    Article  Google Scholar 

  12. Morton DL. Polyvalent melanoma cell vaccines as adjuvant therapy for patients with advanced melanoma. Melanoma Research 1997 Jun; 7 (Suppl. 1): 52

    Article  Google Scholar 

  13. Israel RJ, et al. Phase II and III clinical development of GM2-KLH/QS-21 vaccine for melanoma. Melanoma Research 1997 Jun; 7 (Suppl. 1): 52

    Article  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Malignant melanoma: prevalence increasing and still no magic bullet. Drugs Ther. Perspect 11, 7–10 (1998). https://doi.org/10.2165/00042310-199811040-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-199811040-00003

Search

Navigation